
EDAP TMS S.A. EDAP
$ 4.38
-4.58%
Quarterly report 2024-Q4
added 02-21-2026
EDAP TMS S.A. Total Assets 2011-2026 | EDAP
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets EDAP TMS S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.1 M | 91.5 M | 101 M | 77.2 M | 55.2 M | 53.1 M | 48.7 M | 46.9 M | 46.6 M | 38.6 M | 32.2 M | 26.9 M | 30.4 M | 32.5 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 101 M | 26.9 M | 54.8 M |
Quarterly Total Assets EDAP TMS S.A.
| 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.1 M | 91.5 M | 101 M | - | - | - | 77.2 M | - | - | - | 55.2 M | - | - | - | 53.1 M | - | - | - | 48.7 M | - | 46.7 M | - | 46.9 M | - | 45.7 M | - | 46.6 M | - | 46.7 M | - | 38.6 M | - | 33.9 M | - | 32.2 M | - | - | - | 26.9 M | - | - | - | 30.4 M | - | 30.9 M | - | 32.2 M | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 M | 26.9 M | 51.1 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 13.94 | -0.71 % | $ 2.09 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
39.2 M | $ 14.09 | -7.06 % | $ 381 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
222 M | $ 31.87 | 2.07 % | $ 1.47 B | ||
|
Cognyte Software Ltd.
CGNT
|
498 M | $ 7.0 | 5.74 % | $ 503 M | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Electromed
ELMD
|
53.8 M | $ 24.18 | 1.09 % | $ 204 M | ||
|
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.49 | 2.05 % | $ 121 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
9.36 B | $ 275.33 | 2.19 % | $ 7.77 B | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 40.88 | 2.48 % | $ 6.09 K | ||
|
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 75.65 | 2.97 % | $ 112 B | ||
|
InMode Ltd.
INMD
|
766 M | $ 14.0 | 0.29 % | $ 905 M | ||
|
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.47 | -2.0 % | $ 23.7 M | ||
|
IRadimed Corporation
IRMD
|
98.3 M | $ 102.4 | 1.89 % | $ 1.3 B | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 45.89 | -0.18 % | $ 1.42 B | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
2.61 B | $ 71.26 | 1.38 % | $ 3.89 B | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
91.7 B | $ 97.22 | 0.58 % | $ 125 B | ||
|
Delcath Systems
DCTH
|
76.6 M | $ 9.11 | -10.77 % | $ 260 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
210 M | $ 2.48 | 1.02 % | $ 146 M | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | ||
|
Establishment Labs Holdings
ESTA
|
347 M | $ 77.41 | -1.12 % | $ 2.18 B | ||
|
Insulet Corporation
PODD
|
3.19 B | $ 251.74 | 1.46 % | $ 17.7 B | ||
|
Quanterix Corporation
QTRX
|
425 M | $ 6.7 | 6.52 % | $ 252 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
199 M | $ 18.53 | -0.3 % | $ 121 M | ||
|
Sintx Technologies
SINT
|
15.4 M | $ 2.89 | -1.87 % | $ 10.8 M | ||
|
MiMedx Group
MDXG
|
343 M | $ 4.97 | -5.78 % | $ 735 M |